文献速递物质与行为成瘾儿童青少年精神

远程医疗开具兴奋剂与后续兴奋剂使用障碍风险

Telehealth Prescribing of Stimulants for ADHD and Associated Risk for Later Stimulant and Substance Use Disorders.
PubMed 文献 · Am J Psychiatry · 2025-06-11

本研究为回顾性队列研究,纳入7944例≥12岁ADHD患者,分析远程医疗与面诊开具初始兴奋剂处方与后续物质使用障碍风险的关系。结果发现远程医疗不显著改变总体SUD风险,但初始处方经远程医疗与后续兴奋剂使用障碍风险显著升高相关,该结果需在其他医疗环境重复验证。

要点

  • 远程医疗与面诊开具初始兴奋剂处方相比,后续总体SUD风险无显著差异。
  • 初始兴奋剂处方经远程医疗与后续兴奋剂使用障碍风险显著升高相关(aOR=6.18)。
  • 该兴奋剂使用障碍结果需在其他医疗环境重复验证。

核心结论

  • 远程医疗开具ADHD兴奋剂处方不改变后续总体SUD风险,但初始处方经远程医疗可能提示后续兴奋剂使用障碍风险升高。

研究设计与样本

  • 回顾性队列研究,使用美国东北部一家非营利学术附属医疗系统2020年3月1日至2023年8月25日的电子健康记录数据。
  • 纳入≥12岁ADHD患者且研究期间首次接受任何兴奋剂处方,排除初始处方时已有非尼古丁SUD诊断者,样本7944例。

主要发现

  • 纯远程医疗关系与任何面诊关系相比,后续SUD风险无显著差异(aOR=0.85,95%CI=0.60,1.20)。
  • 纯远程医疗关系与任何面诊关系相比,后续兴奋剂使用障碍风险无显著差异(aOR=1.28,95%CI=0.34,4.85)。
  • 初始兴奋剂处方时远程医疗与面诊相比,后续SUD风险无显著差异(aOR=1.15,95%CI=0.92,1.44)。
  • 初始兴奋剂处方时远程医疗与面诊相比,后续兴奋剂使用障碍风险显著升高(aOR=6.18,95%CI=1.34,28.46)。

临床怎么用

  • 临床中经远程医疗为ADHD患者开具初始兴奋剂处方时,需关注后续兴奋剂使用障碍风险。
  • 该研究结果尤其兴奋剂使用障碍部分需在其他医疗环境重复验证后再用于临床决策。

局限性

  • 研究结果尤其兴奋剂使用障碍部分需在其他医疗环境重复验证。
  • 研究仅基于美国东北部单一非营利学术附属医疗系统的电子健康记录数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The authors sought to determine 1) whether receiving an initial stimulant prescription for attention deficit hyperactivity disorder (ADHD) from a provider whom a patient has never seen in person is associated with increased risk for stimulant use disorder (stimUD) or other substance use disorders (SUDs), and 2) whether receiving an initial stimulant prescription during a telehealth versus in-person appointment is associated with increased risk for stimUD or SUD. METHODS: This was a retrospective cohort study using electronic health record data from March 1, 2020, to August 25, 2023, from a not-for-profit, academically affiliated medical system in the Northeastern United States. Eligible study subjects were ≥12 years old with ADHD and initial receipt of any stimulant prescription during the study period. Exclusion criteria included a non-nicotine SUD diagnosis at the time of initial stimulant prescription. RESULTS: The sample included 7,944 patients. After adjustment for covariates, a purely telehealth-based relationship versus any in-person relationship did not significantly alter risk for SUD (adjusted odds ratio=0.85, 95% CI=0.60, 1.20) or stimUD (adjusted odds ratio=1.28, 95% CI=0.34, 4.85). A telehealth versus in-person appointment at the time of the initial stimulant prescription did not significantly alter risk for subsequent SUD (adjusted odds ratio=1.15, 95% CI=0.92, 1.44) but was associated with significantly higher risk for stimUD (adjusted odds ratio=6.18, 95% CI=1.34, 28.46). CONCLUSIONS: The results suggest that receipt of a stimulant prescription for ADHD via telehealth does not alter the risk for SUD, but receipt of an initial stimulant prescription via telehealth may signal increased risk of subsequent stimUD. The results, particularly for stimUD, require replication in other health care settings.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Rao V, Lanni S, Yule AM, et al. Telehealth Prescribing of Stimulants for ADHD and Associated Risk for Later Stimulant and Substance Use Disorders. Am J Psychiatry. 2025. PMID: 40495525. doi:10.1176/appi.ajp.20240346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。